ESSA’s lead clinical candidate, masofaniten (formerly EPI-7386), is a first-in-class N-terminal domain androgen receptor inhibitor in development for the treatment of androgen receptor (AR)-driven prostate cancer. ESSA believes that by inhibiting both the N-terminal and the ligand-binding domains of AR, greater suppression of androgen biology may be possible potentially delaying the emergence of drug resistance. We are investigating masofaniten in combination trials in patients with prostate cancer. By targeting the AR through two independent pathways, combination therapies have the potential to improve the treatment of prostate cancer and provide a new standard of care for both early and advanced disease.

For more information, please visit